Fresenius Medical Care Ventures was established in early 2016 to invest in start-ups and early-stage companies in the healthcare sector. The investments are targeted to support Fresenius Medical Care’s corporate strategy to grow continuously in our core business and to expand into new business areas. Fresenius Medical Care Ventures is complementing the corporate activities in external innovation.
Fresenius Medical Care Ventures invests in early stage companies that develop products, technologies and therapies which will have a significant value for the patient and for the healthcare system.
Sectors of Interest
Products and technologies of interest include medical devices, patient monitoring, eHealth solutions, regenerative medicine and pharmaceuticals which provide innovative and potentially transformative approaches in the following therapeutic sectors:
Chronic Kidney Disease and Dialysis
Intensive Care Medicine
Fresenius Medical Care Ventures has been launched only recently and is in the process of establishing an active portfolio.
ExThera Medical is developing revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking.
MEDICA HEALTH IT FORUM, November 15, 2016, Düsseldorf, Germany
Fresenius Medical Care Ventures is supporting the eHealth Venture Summit 2016 at the MEDICA Health IT Forum. For the Fresenius Medical Care Venture Challenge we are seeking start-ups in the following domains:
NLP (Natural Language Processing) in Healthcare domain
ExThera Medical Closes Financing Led by Fresenius Medical Care Ventures to Support Commercialization of Innovative Technology to Remove Pathogens from Whole Blood
Martinez, Calif. – June 2, 2016 – ExThera Medical Corporation, the leading developer of innovative blood filtering technology to address major global health problems, today announced that the company has closed a Series B financing round with an equity investment led by new investor Fresenius Medical Care Ventures GmbH. The round included existing investors, and the conversion of the company’s convertible note, for a total of $15.3 million. Other terms were not disclosed.